Needham Remains a Hold on Omeros (OMER)

By Jason Carr

Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMERResearch Report) today. The company’s shares closed last Monday at $13.70.

According to, Belanger is a 1-star analyst with an average return of -1.4% and a 39.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.

Currently, the analyst consensus on Omeros is a Moderate Buy with an average price target of $26.50, which is a 92.3% upside from current levels. In a report issued on October 29, Wedbush also reiterated a Hold rating on the stock with a $18.00 price target.

See today’s analyst top recommended stocks >>

Based on Omeros’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.45 million. In comparison, last year the company had a GAAP net loss of $39.47 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.